{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:56:56Z","timestamp":1773277016568,"version":"3.50.1"},"reference-count":18,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2014.00092","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T11:03:34Z","timestamp":1398942214000},"source":"Crossref","is-referenced-by-count":17,"title":["Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1"],"prefix":"10.3389","volume":"4","author":[{"given":"Markus","family":"Moehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline J.","family":"Breitbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Delic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Rommelaere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"issue":"1","key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt349","article-title":"Immunological off-target effects of standard treatments in gastrointestinal cancers","volume":"25","author":"Duffy","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"issue":"4","key":"B3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ijc.21155","article-title":"CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction","volume":"117","author":"Contardi","year":"2005","journal-title":"Int J Cancer"},{"issue":"12","key":"B4","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res"},{"issue":"6","key":"B5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","article-title":"Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial","volume":"21","author":"Weber","year":"2011","journal-title":"Melanoma Res"},{"issue":"2","key":"B6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.seminoncol.2010.03.001","article-title":"Regional liver therapy using oncolytic virus to target hepatic colorectal metastases","volume":"37","author":"Carpenter","year":"2010","journal-title":"Semin Oncol"},{"issue":"3","key":"B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.cgt.7700288","article-title":"Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors","volume":"8","author":"Moehler","year":"2001","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"B8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/0141076813494196","article-title":"Live viruses to treat cancer","volume":"106","author":"Donnelly","year":"2013","journal-title":"J R Soc Med"},{"issue":"7728","key":"B9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(71)92788-7","article-title":"Viruses in the treatment of cancer","volume":"298","author":"Csatary","year":"1971","journal-title":"Lancet"},{"issue":"8","key":"B10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ctrv.2010.12.003","article-title":"The emerging role of viruses in the treatment of solid tumours","volume":"37","author":"Bourke","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"B11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"11","key":"B12","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1002\/ijc.27938","article-title":"Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1","volume":"132","author":"Sieben","year":"2012","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/1471-2407-11-464","article-title":"Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1","volume":"11","author":"Moehler","year":"2011","journal-title":"BMC Cancer"},{"issue":"8","key":"B14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1089\/hum.2005.16.996","article-title":"Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells","volume":"16","author":"Moehler","year":"2005","journal-title":"Hum Gene Ther"},{"issue":"3","key":"B15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF","volume":"14","author":"Kim","year":"2006","journal-title":"Mol Ther"},{"issue":"4","key":"B16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"issue":"suppl; abstr LBA9008","key":"B17","article-title":"OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB\/C and IV melanoma","volume":"31","author":"Andtbacka","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"B18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T19:43:20Z","timestamp":1424288600000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2014.00092\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":18,"URL":"https:\/\/doi.org\/10.3389\/fonc.2014.00092","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}